OVARIAN CANCER

(1), ovarian cancer-chemotherapy drug commonly used drug <BR> melphalan (PAM) 0.2 ^ / ㎏ d, oral, 4 ~ for a course on the 5th, rest four to six weeks after duplication. Thiotepa (161-169) 10 ^ / times, intramuscular or intravenous injection, used five times, every other day to once a total of 300 ~ 500 days for an induction course. 6 to 8 weeks under the condition repeat. Cyclophosphamide (CTX) 50 ~ 100 ^ / day, oral, 7 ~ 10 Tianyi treatment, two weeks after duplication. Or 400 ^ / day, intravenous, oral to four days. Adriamycin (ADM) 50 ~ 70 ^ / ㎡, intravenous injection. Every three weeks.
(2), and malignant ovarian tumor joint chemical treatment of ovarian cancer chemotherapy are better response. In recent years the chemical treatment of tumors faster progress in the treatment of ovarian cancer Habitat has an important place to improve the treatment of ovarian cancer play a positive role as a surgical adjuvant therapy, commonly used in the preoperative, intraoperative and postoperative, but often require a longer period of intermittent medication, and the human body toxicity also sometimes larger. In most cases, it is difficult to ovarian cancer surgery primary tumor and metastasis consider chemical treatment based treatment.

Tags: body, cancer, cases, chemotherapy, days, drug, eat, injection, intravenous, malignant, metastasis, ovarian, positive, response, surgery, surgical, therapy, time, toxicity, treatment, tumor, tumors

【Medical industry network HealthDayNews2003 According to the July 3 - now on the younger female epithelial ovarian cancer, some important information: your chances of survival much more than older patients.

In July, "Obstetrics and Gynecology" (Obstetrics andGynecology), the journal published a new study, the researchers found: diagnosis of advanced epithelial ovarian cancer in women aged under 45 of the 5-year survival than those over the age of 45 is two times bigger. "If all other aspects of the same, young patients can live better," the author, Stamford University professor Chen (JohnChan): In fact, even if it is possible to study the impact of factors, such as other health problems, age patients still live better.

Tags: age, blood, cancer, clinical, diagnosis, early, gene, group, groups, growth, method, ovarian, patients, positive, rate, response, study, surgery, survival, time, tumor, women

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors

Amenorrhea is common clinical symptoms, their causes are complex, the causes can be divided into the central nervous system and the hypothalamus, pituitary, ovary and uterus of amenorrhea, including congenital Gonadal Dysgenesis and autoimmune ovarian inflammation. As such closure gonadotropin levels often associated with higher estrogen levels decrease, it said hypergonadotropic amenorrhea, gonadotropin levels higher than normal cycle or reached menopause, clinical manifestations of primary or secondary amenorrhea.

Tags: age, amenorrhea, anti, blood, body, cause, clinical, diagnosis, eat, ert, estrogen, examination, gene, ovarian, ovary, patients, pelvic, poor, positive, rate, second, symptoms, time, treatment

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

I. Overview

With the aging of the global trend of development, improve the economic status of women, more and more women start hormone replacement therapy (Hormone Replacement Therapy, HRT), to improve access to after menopause due to the decrease in the level of sex hormones related to various diseases. Clear evidence that: postmenopausal women with age, the incidence of coronary heart disease increased by about four times the fracture due to osteoporosis by 20%, died of complications due to pelvic fracture rate of 30%, after the 65-year-old Alzheimer's incidence rate increase every year <BR> and Application HRT can peer groups coronary heart disease risk 50% Alzheimer's risk reduced three times, especially worth mentioning is significantly reduced the incidence of rectal cancer. Long-term use of HRT cancer risk reduced year by year. HRT can also greatly improve the menopause, postmenopausal women with disease or ovarian surgery, radiotherapy in patients with a series of artificial menopause syndrome.

Tags: age, benign, blood, body, brca1, breast, cancer, carcinoma, care, cases, cause, cell, cells, clinical, cyst, cystic, diagnosis, diet, drug, early, eat, ert, estrogen, family, fat, gene, grams, group, groups, growth, gynecological, history, hrt, incidence, increased, injection, intravenous, life, lymph, malignant, metastasis, method, mutation, node, ovarian, patients, pelvic, positive, protein, quality, radiotherapy, rate, reduce, residual, risk, screening, second, study, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, tumors, usually, uterine, women

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Diagnosis
Not obvious early symptoms of ovarian cancer, so early diagnosis depends on the regular census.

1. Past history should be asked whether particular pelvic mass or the recent history of tumor growth. Women over 40 years of age and unexplained gastrointestinal symptoms, and should be gynecological examinations.
2. Body check, can be found abdominal mass, ascites positive sign.
3. Gynecological examinations beside mass, although it is solid or cystic, irregular activities of the poor, and often bilateral. Triple consultation found dome nodule or mass.
4. Auxiliary

Tags: abdominal, age, anti, benign, body, cancer, carcinoma, cell, cells, cyst, cystic, diagnosis, early, examination, growth, gynecological, history, increased, malignant, mass, ovarian, pelvic, poor, positive, protein, symptoms, tumor, women

Ovarian cancer is common gynecologic cancer, female genital tumors about 1 / 3. Can occur at any age, and women with reproductive seen. The incidence of ovarian cancer is women's genital cancer Habitat third place, as early diagnosis difficult, often found at the already advanced, but the mortality rate for the first gynecologic malignancies.
[Diagnosis]

A Symptoms

(1) abdominal discomfort or medium sized benign tumor rapid growth often cause bloating and discomfort.

(2) abdominal mass benign swelling growth slow, difficult to be discovered, patients are often inadvertently touched. Malignant tumors grow fast, easily detected.

Tags: abdominal, age, anti, benign, bleeding, blood, cancer, carcinoma, cause, cell, cells, cyst, cystic, diagnosis, early, eat, ert, estrogen, examination, gene, growth, incidence, increased, lymph, malignant, mass, metastasis, metastatic, node, oppression, ovarian, ovary, pain, patients, pelvic, positive, rate, reduce, surface, symptoms, tumor, tumors, uterine, women

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment